Clinical Trials Logo

Hyperkinesis clinical trials

View clinical trials related to Hyperkinesis.

Filter by:

NCT ID: NCT00995085 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

Start date: October 2009
Phase: Phase 1
Study type: Interventional

This clinical study is designed to evaluate the safety and tolerability of a single oral administration of a Metadoxine slow release formulation to subjects diagnosed as having ADHD. Study also assess cognitive effects of such drug administration.

NCT ID: NCT00989950 Completed - INSOMNIA Clinical Trials

Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD

Daytsleep
Start date: December 2009
Phase: N/A
Study type: Interventional

Methylphenidate may improve sleep in children with ADHD. By leaving Daytrana (methylphenidate) patch for a longer time then 9 hours, many children report short sleep latencies and better quality of sleep.

NCT ID: NCT00983814 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa

ADD201
Start date: October 2009
Phase: Phase 2
Study type: Interventional

Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, talking out of turn, difficulty waiting and interrupting others. ADHD is the second most common neuropsychiatric disorder affecting 4.4% of the United States (US) adult population, or between 8-9 million individuals. Droxidopa (L-dihydroxyphenylserine (L-DOPS)) is a synthetic catecholamine which is converted to norepinephrine (NE) via decarboxylation, resulting in increased levels of NE centrally in the central nervous system (CNS) and peripherally. Co-treatment with carboxylase inhibitors, such as carbidopa, given with droxidopa, can increase the CNS levels of NE with greater crossing of the blood-brain barrier. Droxidopa has received orphan drug approval by the Food and Drug Administration (FDA) for the treatment of symptomatic neurogenic orthostatic hypotension in individuals with primary autonomic failure. The half-life of droxidopa is approximately 2-3 hours, resulting in administration three times daily.

NCT ID: NCT00969618 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.

NCT ID: NCT00966394 Completed - Xerostomia Clinical Trials

Salivary Bacteria and Oral Health Status in Children With ADHD

ADHD
Start date: November 2009
Phase: N/A
Study type: Observational

Attention deficit and hyperactivity (ADHD) affect 6% of school-aged children. Few studies reported higher prevalence of caries and restorations among children with ADHD. Methylphenidate is the drug of choice to treat ADHD. according to the medical literature methylphenidate can cause xerostomia. Our study will investigate saliva parameters (such as quantity, bacteria in saliva, buffer capacity), oral hygiene and diet habits and their influence on caries among children with ADHD and among healthy children. Our hypothesis is: - Children with ADHD will have more caries. - Children with ADHD will have more detrimental oral hygiene and diet habits. - There will be a difference in the saliva parameters between children with ADHD and healthy children.

NCT ID: NCT00965419 Terminated - Clinical trials for Attention Deficit Hyperactivity Disorder

A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

Start date: September 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).

NCT ID: NCT00962104 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

Start date: August 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).

NCT ID: NCT00956605 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

A Trial of Computer-based Attention-training Systems in Children With Attention Deficit Hyperactivity Disorder (ADHD)

CATS
Start date: May 2006
Phase: N/A
Study type: Interventional

This study examines the efficacy of two computer-based training systems to teach children with ADHD to attend more effectively.

NCT ID: NCT00947973 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This study will compare the efficacy and cost effectiveness of two methods of treating adolescents with attention deficit hyperactivity disorder in school.

NCT ID: NCT00946582 Recruiting - Clinical trials for Attention Deficit/Hyperactivity Disorder

The Therapeutic Effects of Barkley's Parenting Management Program for Taiwanese School-Aged Children With Attention Deficit/Hyperactivity Disorder (ADHD)

Start date: June 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the therapeutic effects of Barkley's parenting management program for Taiwanese school-aged children with ADHD. The investigators hypothesized that Barkley's parenting management program might empower the parents' competence to manage their school-aged children's ADHD-related disturbing behaviors as its previously-proven effects for parents and their preschool-aged children with ADHD.